View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 28, 2020

Todos Medical signs equipment financing deal with AID Genomics

Israel-based in vitro diagnostics company Todos Medical has entered an implementation and equipment financing partnership with a multi-national genomic R&D company AID Genomics to scale up its Covid-19 PCR testing capabilities.

Israel-based in vitro diagnostics company Todos Medical has entered an implementation and equipment financing partnership with a multi-national genomic R&D company AID Genomics to scale up its Covid-19 PCR testing capabilities.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

As part of the agreement, AID Genomics will fund the purchase of the necessary equipment to enable Todos’ clients to meet their capacity requirements.

It will also help Todos to implement best practices to scale up and optimise sample accessioning and data reporting software.

AID has sent key staff from Israel to the US to help Todos in its ongoing US implementation projects.

Additionally, AID Genomics will participate in the net profit of each contract. It will also assist Todos with validating and commercialising its proprietary tests in Israel.

AID Genomics CEO Snir Zano said: “We are excited to enter the US market in partnership with Todos Medical.

“We have developed a proven, scalable solution that can now be implemented via Todos Medical in the US. Now that Todos has reached the level of scale with its clients that justifies a formal relationship, we believe that we can leverage this partnership through Todos’ sales channels and drive significant uptake of our integration solutions and dramatically increase PCR testing capacity for the US.”

AID Genomics specialises in the development of precision medicine for cancers and infectious diseases. The company recently signed a contract with the Ministry of Health in Israel to build and scale-up six HMO laboratories in Israel.

In addition, the company entered a partnership with Tecan Group for delivery of liquid handler machines worldwide.

Todos Medical president and CEO Gerald Commissiong said: “We are very pleased to formally enter into this partnership with AID Genomics that gives us access to proven implementation know-how and stable access to key automation technology that will allow our clients to reach their desired testing capacity.

“We now intend to aggressively pursue new laboratory equipment and reagent supply agreements with access to non-dilutive funding that the AID Genomics relationship brings us so that we can meet the significant testing needs emerging in the US.”

Last month, Todos Medical announced the commercial launch of its TODOS 2019-nCoV RT-qPCR Detection Kit in the US.

In July, the company expanded the agreement with 3D Medicines for Covid-19 testing products.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network